Instrument Inactif

Communiqués ASLAN Pharmaceuticals Limited Taipei Exchange

Actions

6497

KYG054241099

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change	14/06	AQ
ASLAN PHARMACEUTICALS : ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE Form 6 K	14/06	PU
ASLAN Pharmaceuticals : Amendment to Loan Agreement with K2 HealthVentures LLC - Form 6-K	31/05	PU
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference	21/05	AQ
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05	AQ
ASLAN Pharmaceuticals : 1Q2024 Financial Release	09/05	PU
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event	07/05	AQ
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics	02/05	AQ
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab	30/04	AQ
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference	24/04	AQ
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - April 19, 2024	22/04	AQ
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients	22/04	AQ
ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K	22/04	PU
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice	19/04	AQ
ASLAN PHARMACEUTICALS : ANNOUNCES RECEIPT OF NASDAQ NOTICE - Form 6-K	19/04	PU
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and provides corporate update	15/04	AQ
ASLAN Pharmaceuticals : AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENTSM - Form 6-K	12/04	PU
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12/04	AQ
ASLAN PHARMACEUTICALS : REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Form 6-K	12/04	PU
ASLAN Pharmaceuticals : H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	28/03	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ASLAN Pharmaceuticals Limited Taipei Exchange

Actions

6497

KYG054241099

Communiqués

Filtres